Boothbay Fund Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Boothbay Fund Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$435K	Buy	+17,183	New	+$378K	0.01%	1584
2025 Q3	–	Sell	-20,000	Closed	-$473K	–	1841
2025 Q2	$431K	Buy	+20,000	New	+$372K	0.01%	964
2024 Q4	–	Sell	-17,157	Closed	-$264K	–	1445
2024 Q3	$264K	Buy	+17,157	New	+$286K	0.01%	1306
2023 Q2	–	Sell	-12,856	Closed	-$242K	–	1739
2023 Q1	$242K	Sell	12,856 -45,253	-78%	-$862K	0.01%	1630
2022 Q4	$925K	Hold	58,109	–	–	0.02%	930
2022 Q3	$951K	Buy	+58,109	New	+$941K	0.02%	901
2021 Q4	–	Sell	-28,434	Closed	-$472K	–	1815
2021 Q3	$472K	Sell	28,434 -7,193	-20%	-$139K	0.01%	1120
2021 Q2	$869K	Buy	35,627 +18,225	+105%	+$411K	0.03%	767
2021 Q1	$449K	Buy	17,402 +11,621	+201%	+$512K	0.02%	991
2020 Q4	$309K	Sell	5,781 -891	-13%	-$44.2K	0.01%	939
2020 Q3	$275K	Buy	+6,672	New	+$288K	0.02%	832
2018 Q4	–	Sell	-14,893	Closed	-$309K	–	636
2018 Q3	$309K	Buy	+14,893	New	+$234K	0.03%	496

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Boothbay Fund Management's ACAD Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 17,183 shares worth $435K. The stake represents 0.01% of the portfolio and ranks #1584 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in ACAD as recently as Q2 2025.

Boothbay Fund Management first reported a position in ACAD in Q3 2018 and has held it in 12 quarters since. The position peaked at $951K in Q3 2022. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Boothbay Fund Management held 17,183 shares of Acadia Pharmaceuticals worth $435K as of Q2 2026.
Acadia Pharmaceuticals was a new Boothbay Fund Management position in Q2 2026.
Acadia Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1584 holding.
Boothbay Fund Management first reported a position in Acadia Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
Boothbay Fund Management's Acadia Pharmaceuticals position peaked at $951K in Q3 2022.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.